Entos Pharmaceuticals Inc. is an active federal corporation (corporation number 7872372). Its business number is 816561112. It was incorporated on May 25, 2011 under the Canada Business Corporations Act and its registered office is in Toronto, Ontario. Its annual returns are up to date, most recently for 2026. It has two directors on record.
Corporate details
- Corporation number
- 7872372
- Business number
- 816561112
- Status
- Active
- Governing law
- Canada Business Corporations Act
- Incorporated
- May 25, 2011
- Corporation type
- Non-distributing corporation with 50 or fewer shareholdersAs declared in its 2021 annual return.
- Registered office
- 200 Bay Street
South Tower, Suite 2800
Toronto ON M5J 2J3 - Number of directors
- At least 1, at most 10As the articles allow.
Annual filings
- Anniversary date
- May 25The date of incorporation, amalgamation or continuance.
- Annual filing period
- May 25 to Jul 24 each year
- Last annual meeting
- May 25, 2020
| Year | Annual return | Annual meeting |
|---|---|---|
| 2026 | Filed |
The last annual return filed, and each year since.
Directors
Loading the directors from the federal record...
Federal grants and contributions
10 agreements since 2018, worth $88,648,300 in all.
| Department | Program | Value | Starts |
|---|---|---|---|
| National Research Council Canada | Development of an Inhaled Genetic Medicine for Pre-Exposure Prophylaxis of H5N1 Influenza | $764,000 | Nov 3, 2025 |
| National Research Council Canada | UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies | $130,700 | Aug 1, 2025 |
| National Research Council Canada | In Vivo Validation of Fusogenix Formulations Optimized for Delivery of Genetic Medicines to the Trabecular Meshwork of the Eye | $250,000 | Apr 1, 2025 |
| Innovation, Science and Economic Development Canada | Innovation and Biomanufacturing Centre project | $62,000,000 | Feb 13, 2025 |
| National Research Council Canada | MNC Collab - FOCUS2024 - Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye | $75,000 | Nov 1, 2024 |
| National Research Council Canada | COVID-19 Vaccine: Phase 3 Clinical Trial of DNA-Based Vaccine Booster Covigenix VAX-001-1c | $10,000,000 | Sep 1, 2022 |
| National Research Council Canada | COVID-19 Vaccine: Phase 2 clinical trial of DNA-based vaccine Covigenix VAX-001 | $5,200,000 | Nov 1, 2021 |
| National Research Council Canada | COVID-19 Vaccine: Phase 1 clinical trial of DNA-based vaccine Covigenix VAX-001 | $10,000,000 | Sep 1, 2020 |
| National Research Council Canada | COVID-19 Response: Rapid Prototyping and Deployment of a Fusogenix Vaccine and Immuno-therapeutic against COVID-19 | $100,000 | May 1, 2020 |
| National Research Council Canada | Towards Single-Step manufacturing of LNP Gene Therapy | $128,600 | Oct 1, 2018 |
As each federal department publishes them (proactive disclosure). A value is the agreement's total as last amended; the money may be paid over several years. Search every federal grant.
Names
| Name | Form | In use since |
|---|---|---|
| Entos Pharmaceuticals Inc. | Name | May 25, 2011 |
Filings and certificates
| What | Date |
|---|---|
| Articles amended | Apr 27, 2022 |
| Revived | May 11, 2016 |
| Incorporated | May 25, 2011 |
Registered in a province as well? Find provincial registrations(opens in a new tab). Something wrong or out of date? Request a correction.